Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor gamma joining segment JP2 is a **joining (J) gene segment** located within the human T cell receptor gamma (TRG) locus[1]. It is not a protein-coding gene nor a druggable protein but rather one of several genomic segments (including JP1, JP, J1, J2) involved in VJ recombination. This recombination process assembles the variable (V) and joining (J) elements to generate the diversity of the T cell receptor gamma chains, which are essential for antigen recognition by a subset of T cells known as γδ T cells[1][2][3]. JP2—and other similar J segments—do not encode functional receptors themselves and are not considered therapeutic targets, receptors, enzymes, or druggable entities[2]. Thus, they serve as genomic building blocks for immunological diversity but are not used as direct biomarkers or manipulated by drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor gamma joining segment JP2 (TRGJP2).